A study presented at an Alzheimer's disease conference found that CHF5074, an experimental gamma-secretase modulator, may improve the executive and verbal memory functions of patients with mild cognitive impairment. CHF5074 also appears to have potential in partially restoring the immune response of the brain. "We think that this medication may be a start, the first step -- perhaps a baby step -- in preventing the memory loss that of course is the classic hallmark that Dr. Alzheimer described in the early 1900s," researcher Dr. Joel Ross said.

Related Summaries